FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766101652> ?p ?o ?g. }

• W2766101652 endingPage "935" @default.
• W2766101652 startingPage "922" @default.
• W2766101652 abstract "Half of patients with pancreatic adenocarcinoma (PC) present with regionally advanced disease. This includes borderline resectable and locally advanced unresectable tumors as defined by current NCCN guidelines for resectability. Chemoradiation (CH-RT) is used in this setting in attempt to control local disease, and possibly downstage to resectable disease. We report a phase I/II trial of a combination of 5FU/Oxaliplatin with concurrent radiation in patients presenting with borderline resectable and locally advanced unresectable pancreatic cancer.Patients with biopsy-proven borderline resectable or locally advanced unresectable PC were eligible. Chemotherapy included continuous infusion 5FU (200 mg/m2) daily and oxaliplatin weekly for 5 weeks in dose escalation cohorts, ranging from 30 to 60 mg/m2. Concurrent radiation therapy consisted of 4,500 cGy in 25 fractions (180 cGy/fx/d) followed by a comedown to the tumor and margins for an additional 540 cGy ×3 (total dose 5,040 cGy in 28 fractions). Following completion of CH-RT, patients deemed resectable underwent surgery; those who remained unresectable for cure but did not progress (SD, stable disease) received mFOLFOX6 ×6 cycles. Survival was calculated using Kaplan-Meier analysis. End-points of the phase II portion were resectability and overall survival.Overall, 24 subjects (15 men and 9 women, mean age 64.5 years) were enrolled between June 2004 and December 2009 and received CH-RT. Seventeen patients were enrolled in the Phase I component of the study, fifteen of whom completed neoadjuvant therapy. Reasons for not completing treatment included grade 3 toxicities (1 patient) and withdrawal of consent (1 patient). The highest dose of oxaliplatin (60 mg/m2) was well tolerated and it was used as the recommended phase II dose. An additional 7 patients were treated in the phase II portion, 5 of whom completed CH-RT; the remaining 2 patients did not complete treatment because of grade 3 toxicities. Overall, 4/24 did not complete CH-RT. Grade 4 toxicities related to initial CH-RT were observed during phase I (n=2, pulmonary embolism and lymphopenia) and phase II (n=3, fatigue, leukopenia and thrombocytopenia). Following restaging after completion of CH-RT, 4 patients had progressed (PD); 9 patients had SD and received additional chemotherapy with mFOLFOX6 (one of them had a dramatic response after two cycles and underwent curative resection); the remaining 7 patients (29.2%) were noted to have a response and were explored: 2 had PD, 4 had SD, still unresectable, and 1 patient was resected for cure with negative margins. Overall 2 patients (8.3%) in the study received curative resection following neoadjuvant therapy. Median overall survival for the entire study population was 11.4 months. Overall survival for the two resected patients was 41.7 and 21.6 months.Combined modality treatment for borderline resectable and locally advanced unresectable pancreatic cancer with oxaliplatin, 5FU and radiation was reasonably well tolerated. The majority of patients remained unresectable. Survival data with this regimen were comparable to others for locally advanced pancreas cancer, suggesting the need for more novel approaches." @default.
• W2766101652 created "2017-11-10" @default.
• W2766101652 creator A5004828861 @default.
• W2766101652 creator A5015750678 @default.
• W2766101652 creator A5020119107 @default.
• W2766101652 creator A5030301998 @default.
• W2766101652 creator A5030753298 @default.
• W2766101652 creator A5045102551 @default.
• W2766101652 creator A5048973199 @default.
• W2766101652 creator A5071335916 @default.
• W2766101652 creator A5073180877 @default.
• W2766101652 date "2018-10-01" @default.
• W2766101652 modified "2023-10-05" @default.
• W2766101652 title "Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation" @default.
• W2766101652 cites W130029957 @default.
• W2766101652 cites W1530374458 @default.
• W2766101652 cites W1856551192 @default.
• W2766101652 cites W1894182878 @default.
• W2766101652 cites W1955000909 @default.
• W2766101652 cites W2003032215 @default.
• W2766101652 cites W2011285680 @default.
• W2766101652 cites W2012005360 @default.
• W2766101652 cites W2016236483 @default.
• W2766101652 cites W2022501291 @default.
• W2766101652 cites W2024477013 @default.
• W2766101652 cites W2028547579 @default.
• W2766101652 cites W2029242108 @default.
• W2766101652 cites W2040174837 @default.
• W2766101652 cites W2044211072 @default.
• W2766101652 cites W2045505194 @default.
• W2766101652 cites W2054625398 @default.
• W2766101652 cites W2061142163 @default.
• W2766101652 cites W2071258820 @default.
• W2766101652 cites W2084800358 @default.
• W2766101652 cites W2097642908 @default.
• W2766101652 cites W2101345979 @default.
• W2766101652 cites W2103711657 @default.
• W2766101652 cites W2107962449 @default.
• W2766101652 cites W2109857081 @default.
• W2766101652 cites W2121368761 @default.
• W2766101652 cites W2121761389 @default.
• W2766101652 cites W2129056290 @default.
• W2766101652 cites W2129791148 @default.
• W2766101652 cites W2151253787 @default.
• W2766101652 cites W2154320994 @default.
• W2766101652 cites W2154574630 @default.
• W2766101652 cites W2155637224 @default.
• W2766101652 cites W2165480504 @default.
• W2766101652 cites W2167628315 @default.
• W2766101652 cites W2171950337 @default.
• W2766101652 cites W2172089182 @default.
• W2766101652 cites W2235523093 @default.
• W2766101652 cites W2311663614 @default.
• W2766101652 cites W2340641404 @default.
• W2766101652 cites W2345822778 @default.
• W2766101652 cites W2413386818 @default.
• W2766101652 cites W2424140724 @default.
• W2766101652 cites W4229719081 @default.
• W2766101652 cites W4290357395 @default.
• W2766101652 doi "https://doi.org/10.21037/jgo.2017.10.04" @default.
• W2766101652 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6219979" @default.
• W2766101652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30505595" @default.
• W2766101652 hasPublicationYear "2018" @default.
• W2766101652 type Work @default.
• W2766101652 sameAs 2766101652 @default.
• W2766101652 citedByCount "4" @default.
• W2766101652 countsByYear W27661016522019 @default.
• W2766101652 countsByYear W27661016522020 @default.
• W2766101652 countsByYear W27661016522023 @default.
• W2766101652 crossrefType "journal-article" @default.
• W2766101652 hasAuthorship W2766101652A5004828861 @default.
• W2766101652 hasAuthorship W2766101652A5015750678 @default.
• W2766101652 hasAuthorship W2766101652A5020119107 @default.
• W2766101652 hasAuthorship W2766101652A5030301998 @default.
• W2766101652 hasAuthorship W2766101652A5030753298 @default.
• W2766101652 hasAuthorship W2766101652A5045102551 @default.
• W2766101652 hasAuthorship W2766101652A5048973199 @default.
• W2766101652 hasAuthorship W2766101652A5071335916 @default.
• W2766101652 hasAuthorship W2766101652A5073180877 @default.
• W2766101652 hasBestOaLocation W27661016522 @default.
• W2766101652 hasConcept C121608353 @default.
• W2766101652 hasConcept C126322002 @default.
• W2766101652 hasConcept C141071460 @default.
• W2766101652 hasConcept C2776694085 @default.
• W2766101652 hasConcept C2778822529 @default.
• W2766101652 hasConcept C2780210213 @default.
• W2766101652 hasConcept C2780962732 @default.
• W2766101652 hasConcept C2781182431 @default.
• W2766101652 hasConcept C31760486 @default.
• W2766101652 hasConcept C509974204 @default.
• W2766101652 hasConcept C526805850 @default.
• W2766101652 hasConcept C71924100 @default.
• W2766101652 hasConceptScore W2766101652C121608353 @default.
• W2766101652 hasConceptScore W2766101652C126322002 @default.
• W2766101652 hasConceptScore W2766101652C141071460 @default.
• W2766101652 hasConceptScore W2766101652C2776694085 @default.
• W2766101652 hasConceptScore W2766101652C2778822529 @default.
• W2766101652 hasConceptScore W2766101652C2780210213 @default.

• next